老虎证券

BUZZ-Silexion Therapeutics climbs on promising cancer drug data

Reuters
2025/09/30
BUZZ-Silexion <a href="https://laohu8.com/S/LENZ">Therapeutics</a> climbs on promising cancer drug data

** Shares of drug developer Silexion Therapeutics SLXN.O rise 11% to $3.75 premarket

** Says its experimental cancer drug, SIL204, showed strong activity in lab tests, targeting a wide range of KRAS mutations linked to aggressive cancers

** Reports inhibition rates between 83.5% and 99.7% in 11 human cancer cell lines, including its first data in gastric cancer and expanded results in colorectal cancer

** SIL204 also showed high potency against the G12R mutation, which affects about 17% of pancreatic cancer patients

** Plans to start mid-to-late stage trials in the first half of 2026

** As of last close, stock down 88% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10